Castle Biosciences (NASDAQ:CSTL) Stock Crosses Above 50-Day Moving Average – Here’s Why

Castle Biosciences, Inc. (NASDAQ:CSTL)’s stock price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $34.27 and traded as high as $34.46. Castle Biosciences shares last traded at $34.38, with a volume of 563,377 shares traded.

Key Castle Biosciences News

Investors following CSTL have been watching these news items:

• Positive Sentiment: Castle said analyses to be presented at dermatology conferences indicate DecisionDx-Melanoma can identify higher-risk patients among people with thin melanomas and provide individualized five-year recurrence-risk estimates for stage I–III melanoma. The findings may reinforce the test’s clinical value and potential to inform patient monitoring, though the announcement describes data presentations rather than new commercial results. Article: DecisionDx-Melanoma Data at SDPA and Dermato-Onco2026
• Positive Sentiment: Analyst sentiment is favorable: BTIG raised its price target to $52 and maintained a Buy rating, while Canaccord Genuity also issued a Buy rating. These ratings may support investor confidence, but targets are opinions, not guarantees. Article: BTIG Research rating and price target Article: Canaccord Genuity Buy rating
• Neutral Sentiment: Castle’s management is scheduled to present at the Piper Sandler Healthcare Conference on Dec. 2. The appearance may provide an opportunity for updates, but no new business or financial information was announced. Article: Castle Biosciences to Present at the Piper Sandler Conference

Wall Street Analyst Weigh In

Several analysts recently weighed in on CSTL shares. Mizuho started coverage on Castle Biosciences in a report on Thursday, October 29th. They set an “outperform” rating and a $60.00 price target for the company. BTIG Research upped their price objective on Castle Biosciences from $44.00 to $52.00 and gave the company a “buy” rating in a report on Monday. Robert W. Baird upped their price objective on Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a report on Monday. KeyCorp increased their price objective on Castle Biosciences from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, November 6th. Finally, Wall Street Zen raised Castle Biosciences from a “hold” rating to a “buy” rating in a report on Sunday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $46.50.

Castle Biosciences Stock Performance

The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -44.14 and a beta of 1.00. The company has a quick ratio of 5.12, a current ratio of 5.28 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $34.30 and a 200 day simple moving average of $28.42.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.22. Castle Biosciences had a negative net margin of 6.10% and a negative return on equity of 4.89%. The firm had revenue of $101.95 million for the quarter, compared to analyst estimates of $92.76 million. As a group, equities research analysts forecast that Castle Biosciences, Inc. will post -0.83 EPS for the current year.

Insiders Place Their Bets

In other news, insider Derek Maetzold sold 8,580 shares of the business’s stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $31.91, for a total value of $273,787.80. Following the sale, the insider owned 12,484 shares of the company’s stock, valued at $398,364.44. The trade was a 40.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Tobin W. Juvenal sold 6,578 shares of the business’s stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $36.42, for a total transaction of $239,570.76. Following the sale, the insider directly owned 38,853 shares in the company, valued at $1,415,026.26. The trade was a 14.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 126,184 shares of company stock valued at $4,324,506. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Assetmark Inc. lifted its position in Castle Biosciences by 9.3% in the 1st quarter. Assetmark Inc. now owns 5,779 shares of the company’s stock worth $142,000 after buying an additional 492 shares during the last quarter. Allworth Financial LP grew its position in Castle Biosciences by 255.3% during the third quarter. Allworth Financial LP now owns 938 shares of the company’s stock valued at $33,000 after acquiring an additional 674 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Castle Biosciences by 15.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,574 shares of the company’s stock valued at $194,000 after acquiring an additional 747 shares during the last quarter. NFSG Corp bought a new position in Castle Biosciences during the third quarter valued at approximately $36,000. Finally, Global Retirement Partners LLC purchased a new position in shares of Castle Biosciences during the second quarter worth approximately $26,000. 92.60% of the stock is owned by institutional investors.

About Castle Biosciences

Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.